scholarly journals Use of Bone Marrow Aspirate Concentrate (BMAC) Associated with Hyperbaric Oxygenation Therapy in Maxillary Appositional Bone Reconstruction. A Randomized Clinical Trial

Symmetry ◽  
2018 ◽  
Vol 10 (10) ◽  
pp. 533
Author(s):  
Antonio Carlos Aloise ◽  
Paulo Pasquali ◽  
Marcelo Sperandio ◽  
Luis Guilherme Scavone de Macedo ◽  
Marcelo Lucchesi Teixeira ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Hyperbaric Oxygenation ◽  
Bone Marrow Aspirate ◽  
Control Group ◽  
Bone Block ◽  
Bone Reconstruction ◽  
Mineralized Tissue ◽  
Bone Marrow Aspirate Concentrate ◽  
Bone Biopsies ◽  
The Difference

Objectives: The objective of this study was to evaluate bone reconstruction using xenograft alone and associated with bone marrow aspirate concentrate (BMAC) and hyperbaric oxygen therapy. Material and Methods: Twenty-four maxillary edentulous patients were randomly assigned into three groups: Control group (CG)—xenograft bone alone (n = 8); Group 1 (G1)—xenogeneic bone block combined with BMAC (n = 8), and Group 2 (G2)—xenogeneic bone block combined with BMAC and hyperbaric oxygenation (n = 8). Bone biopsies were harvested 6 months after grafting. Vital Mineralized Tissue (VMT), Non-vital Mineralized Tissue (NVMT), and Non-Mineralized Tissue (NMT) were measured. Computed tomography was also performed on three occasions T0 (preoperative), T4 (4 months postoperative), and T8 (8 months postoperative). The difference between T4 and T8 values with respect to T0 was used to determine the thickness level gain after 4 and 8 months, respectively. Results: The tomographic evaluation did not show significant differences between the groups either at 4 or at the 8 months postoperatively. Regarding the histomorphometric analysis, CG had the lowest percentages of VMT (36.58 ± 9.56%), whereas G1 and G2 had similar results (55.64 ± 2.83% and 55.30 ± 1.41%, respectively). Concerning NMT and NVMT levels, the opposite was observed, with CG levels of 51.21 ± 11.54% and 11.16 ± 2.37%, G1 of 39.76 ± 11.48% and 3.65 ± 0.87%, and G2 of 40.3 ± 11.48% and 4.10 ± 0.87%, respectively. Conclusions: The use of bone block xenograft associated with BMAC resulted in a significant increase of bone neoformation when compared to the xenograft alone, though hyperbaric oxygenation did not enhance the results.

scholarly journals Maxillary Sinus Augmentation Combining Bio-Oss with the Bone Marrow Aspirate Concentrate: A Histomorphometric Study in Humans

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Paulo José Pasquali ◽  
Marcelo Lucchesi Teixeira ◽  
Thiago Altro de Oliveira ◽  
Luis Guilherme Scavone de Macedo ◽  
Antonio Carlos Aloise ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Aspirate ◽  
Test Group ◽  
Controlled Study ◽  
Control Group ◽  
Mineralized Tissue ◽  
Sinus Augmentation ◽  
Bone Marrow Aspirate Concentrate ◽  
Bone Biopsies ◽  
Sinus Floor

Purpose. To investigate the regenerative results obtained with the association of bone marrow aspirate concentrate using the Bone Marrow Aspirate Concentrate (BMAC) method to a xenogeneic bone graft (Bio-Oss) in sinus floor elevation.Materials and Methods. Using a randomized controlled study design in eight consecutive patients (age of 55.4 ± 9.2 years), 16 sinus floor lift procedures were performed with Bio-Oss alone (control group, CG,n=8) or combined with bone marrow aspirate concentrate obtained via the BMAC method (test group, TG,n=8). Six months after the grafting procedures, bone biopsies were harvested during implant placement and were analyzed by histomorphometry.Results. Histomorphometric analysis revealed a significantly higher amount(p<0.05)of vital mineralized tissue in TG when compared to the CG (55.15 ± 20.91% and 27.30 ± 5.55%, resp.). For nonvital mineralized tissue, TG presented a statistically higher level of Bio-Oss resorption(p<0.05)when compared with the CG (6.32 ± 12.03% and 22.79 ± 9.60%, resp.). Both groups (TG and CG) showed no significantly different levels (p>0.05) of nonmineralized tissue (38.53 ± 13.08% and 49.90 ± 7.64%, resp.).Conclusion. The use of bone marrow concentrate obtained by BMAC method increased bone formation in sinus lift procedures.

Enhancement of Healing of Long Tubular Bone Defects in Rabbits Using a Mixture of Atelocollagen Gel and Bone Marrow Aspirate Concentrate

2017 ◽  
Vol 203 (6) ◽  
pp. 339-352 ◽  
Author(s):  
Ho Youn Park ◽  
Asode Ananthram Shetty ◽  
Jang Mook Kim ◽  
Young Ju Kim ◽  
Jae-Deog Jang ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Aspirate ◽  
Bone Defects ◽  
Control Group ◽  
Tubular Bone ◽  
Bone Marrow Aspirate Concentrate ◽  
Defect Healing ◽  
Bone Defect Healing ◽  
New Zealand White Rabbits ◽  
Experimental Group

We evaluated the bone-forming potential of a mixture of atelocollagen and bone marrow aspirate concentrate which was transplanted into bone defects. Radial shaft defects of about 10 mm in size were created in 30 New Zealand white rabbits. Ten rabbits in the control group were not treated further, 10 rabbits in the first experimental group (E1) received an atelocollagen injection, and 10 rabbits in the second experimental group (E2) received an injection of a mixture of atelocollagen and bone marrow aspirate concentrate. The groups were compared radiologically at 8 weeks. Osteogenesis in group E2 progressed more rapidly than that in the other groups, and osteogenesis in group E1 progressed faster than that in the control group. Thus, the administration of a mixture of atelocollagen and bone marrow aspirate concentrate in bone defects was found to enhance bone defect healing.

scholarly journals Radiological outcome of hamstring graft after anterior cruciate ligament reconstruction with augmentation of bone marrow aspirate concentrate

2021 ◽  
Vol 7 (2) ◽  
pp. 376
Author(s):  
D. S. Bhamare ◽  
Girish Nathani ◽  
Ishan Shevate ◽  
Clevio Desouza ◽  
Amol Patil
Keyword(s):  
Bone Marrow ◽  
Anterior Cruciate Ligament ◽  
Acl Reconstruction ◽  
Bone Marrow Aspirate ◽  
Cruciate Ligament ◽  
Control Group ◽  
Hamstring Graft ◽  
Bone Marrow Aspirate Concentrate ◽  
Graft Healing ◽  
Anterior Cruciate

<p class="abstract"><strong>Background:</strong> Anterior cruciate ligament (ACL) tears are common injuries in the athletic population. Surgical intervention is required for ACL tears as it restores the knee function and it prevents early osteoarthritis. In the recent research there is increasing use of bone marrow aspirate concentrate in orthopaedics. Bone marrow aspirate concentrate (BMAC) provides mesenchymal stem cells progenitor cells and growth factors which has potential benefits in hamstring graft healing after ACL reconstruction.</p><p class="abstract"><strong>Methods:</strong> This was a prospective randomized case control study carried out between May 2017 and June 2020. 30 patients between age group of 18 to 40 years with complete ACL tear were divided into two groups which consisted of the control group in which only ACL reconstruction was done and second group in which ACL reconstruction was done augmenting it with bone marrow aspirate concentrate. For the BMAC group, 3 ml of BMAC was obtained in the operation theatre itself and was injected into femoral tunnel and the tibia tunnel just before portal suturing. MRI was obtained post operatively at 6 months and at 1 year. Graft healing was seen as the time taken for the graft to reach ligamentization phase when the graft became hyper intense or was visualized similar to PCL or the remnant which was preserved during reconstruction in all cases.<strong></strong></p><p class="abstract"><strong>Results:</strong> Most of the patients in which augmentation (86%) was done healed at 6 month as compared to those who were not augmented (13%).</p><p class="abstract"><strong>Conclusions:</strong> BMAC showed faster and better healing of the graft in ACL reconstruction.</p>

scholarly journals Effectiveness of Platelet-Rich Plasma and Bone Marrow Aspirate Concentrate as Treatments for Chronic Hindlimb Proximal Suspensory Desmopathy

2021 ◽  
Vol 8 ◽  
Author(s):  
Grigorios Maleas ◽  
Mahmoud Mageed
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Aspirate ◽  
Platelet Rich Plasma ◽  
Performance Level ◽  
Control Group ◽  
Bone Marrow Aspirate Concentrate ◽  
Long Term Follow Up ◽  
Short And Long Term

This retrospective study aimed to evaluate the clinical effect of bone marrow aspirate concentrate (BMAC) and leukocyte rich PRP (LR-PRP) compared to horses undergoing controlled exercise alone in horses with &gt;3 months proximal suspensory desmopathy in hindlimbs (HPSD). Nighty-three horses were divided into three groups according to the treatment: a control (n = 22), LR-PRP (n = 46), and BMAC (n = 25) group. Lameness and ultrasound scores were recorded before treatment (T0) and at 6 months (T1) post-treatment. Records horses considered sound at evaluation and level of performance were additionally registered at 12 months (T2) and 18 months (T3) after treatment. The BMAC cytology profiles from 22 horses were also analysed and compared to clinical outcomes. The results at T1 showed that 9% (2/22) of the horses in the control group were sound compared to 59% (25/46) and 84% (21/25) in the LR-PRP and BMAC groups, respectively. Additionally, ultrasound scores at T1 in the BMAC and LR-PRP groups were improved in comparison with the control group (p = 0.02). At T2, 68% of the horses in the BMAC group and 39% of the horses in the LR-PRP group had returned to the previous performance level. At T3, a significantly higher percentage of horses in the LR-PRP (43%) and BMAC (72%) group were sound when compared to the control (4.6%) group (p = 0.02). Similarly, at T3, significantly more horses of the BMAC (16/25) and of the LR-PRP (15/46) group had returned to the previous or a higher performance level compared to the control (1/22) group (p = 0.01). No correlation was found between long-term clinical outcome and cytology profiles in the BMAC group. In conclusion, long-term outcomes of treatment with LR-PRP or BMAC are significantly better than conventional treatment of the hindlimb chronic PSD in horses. Additionally, BMAC yielded better lameness scores than LR-PRP at short- and long-term follow-up.

BONE MARROW ASPIRATE CONCENTRATE INJECTION OF THE ACHILLES TENDON IN A COMPETITIVE DISTANCE RUNNER

2021 ◽  
pp. 2140004
Author(s):  
Kathryn A. Farina ◽  
Blake A. Kandah ◽  
Nan M. Sowers ◽  
Gregory A. Moore
Keyword(s):  
Bone Marrow ◽  
Achilles Tendon ◽  
Bone Marrow Aspirate ◽  
Return To Sport ◽  
Distance Runner ◽  
Complication Rates ◽  
Bone Marrow Aspirate Concentrate ◽  
Progressive Return ◽  
Competitive Athletes ◽  
Lateral Margins

Achilles tendon disorders, including tendinopathy and ruptures, are common among competitive runners. Relatively high complication rates, recurring injuries, and the need to return to sport have led to the use of regenerative medical treatment in tendon disorders in competitive athletes. Biologic therapies, including bone marrow aspirate concentrate (BMAC) injections, have been effective in restoring injured tissue in a limited number of cases. In this case, a collegiate cross country runner with Achilles tendon pain underwent years of failed, non-surgical conservative management. The patient’s MRI demonstrated moderate distal calcaneus tendinosis with high-grade partial thickness tearing of the anterior fibers of the Achilles tendon (50% tear). The patient underwent peritendinous injection of BMAC. Post-procedure MRI demonstrated minimal tendinosis of the distal and lateral margins of the Achilles tendon, and no evidence of Achilles tendon tear. The patient followed a progressive return to running program, ultimately training 40 miles per week with minimal Achilles tendon pain.

Sign in / Sign up

Export Citation Format

Share Document